DISOPYRAMIDE PHOSPHATE | N017447 | PFIZER INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Withdrawal of Approval of 128 Suitability Petitions FDA-1995-P-0005 The Food and Drug Administration is withdrawing approval of 128 suitability petitions under the Pediatric Research Equity Act of 2003, a regulatory mechanism that permits abbreviated new drug applications for drugs with different active ingredients, dosage forms, or routes of administration than the | Safety Withdrawal | 2007-03-06 | Granted | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$1.52
per ea
Lowest NADAC/Unit
$0.7389
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 59762040001DISOPYRAMIDE 150 MG CAPSULE | $1.52 | EA | Generic | — | 2026-10-21 |
| 59762038601DISOPYRAMIDE 100 MG CAPSULE | $0.7389 | EA | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.